{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:47:05Z","timestamp":1740134825862,"version":"3.37.3"},"reference-count":10,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3,18]]},"DOI":"10.1182\/blood.2020010320","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T15:40:55Z","timestamp":1616082055000},"page":"1433-1434","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Protect our children: Hodgkin lymphoma survivors"],"prefix":"10.1182","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8470-394X","authenticated-orcid":false,"given":"Nancy L.","family":"Bartlett","sequence":"first","affiliation":[{"name":"Washington University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"11","key":"2021031815354215700_B1","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1182\/blood.2020007225","article-title":"Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children\u2019s Oncology Group","volume":"137","author":"Giulino-Roth","year":"2021","journal-title":"Blood"},{"issue":"16","key":"2021031815354215700_B2","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: Final results of the randomized EORTC\/LYSA\/FIL H10 Trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"2021031815354215700_B3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(18)30903-3","article-title":"Risk of subsequent primary neoplasms in survivors of adolescent and young adult cancer (Teenage and Young Adult Cancer Survivor Study): a population-based, cohort study","volume":"20","author":"Bright","year":"2019","journal-title":"Lancet Oncol"},{"issue":"8","key":"2021031815354215700_B4","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/cncr.31807","article-title":"Risk of solid subsequent malignant neoplasms after childhood Hodgkin lymphoma-Identification of high-risk populations to guide surveillance: A report from the Late Effects Study Group","volume":"125","author":"Holmqvist","year":"2019","journal-title":"Cancer"},{"issue":"26","key":"2021031815354215700_B5","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"2021031815354215700_B6","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2009.24.8062","article-title":"Second malignant neoplasms in survivors of pediatric Hodgkin\u2019s lymphoma treated with low-dose radiation and chemotherapy","volume":"28","author":"O\u2019Brien","year":"2010","journal-title":"J Clin Oncol"},{"issue":"18","key":"2021031815354215700_B7","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.2016.70.9410","article-title":"Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: Updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials","volume":"35","author":"Sasse","year":"2017","journal-title":"J Clin Oncol"},{"article-title":"SEER Cancer Statistics Review, 1975-2017, National Cancer Institute","volume-title":"Bethesda, MD. Based on November 2019 SEER data submission, posted to the SEER web site April 2020","author":"Howlader","key":"2021031815354215700_B8"},{"issue":"4","key":"2021031815354215700_B9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"2021031815354215700_B10","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1182\/bloodadvances.2019001367","article-title":"KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"4","author":"Armand","year":"2020","journal-title":"Blood Adv"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/11\/1433\/1803243\/bloodbld2020010320c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/11\/1433\/1803243\/bloodbld2020010320c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T15:41:05Z","timestamp":1616082065000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/11\/1433\/475494\/Protect-our-children-Hodgkin-lymphoma-survivors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,3,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020010320","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2021,3,18]]}}}